

June 28, 2026 07:18 PM GMT

Electronic Components | Japan

Investor Visits in Singapore & Hong Kong

We held 31 one-on-one meetings with institutional investors in Singapore and Hong Kong during June 22–26, and a group lunch meeting with institutional investors in both Singapore and Hong Kong, mainly discussing MLCCs and ABF package substrates.

Key Takeaways

- We expect Murata Mfg's MLCCs to continue to see ASP growth driven by improvements and changes in product mix; our rating remains OW.
- The gap in corporate value between companies that implement price hikes readily and those that continuously enhance product competitiveness is likely to become more pronounced
- While we expect Ibiden to continue expanding earnings, market consensus appears too high. Our rating remains UW.

Discussions focused mainly on MLCC and ABF package substrates: We assign investment ratings to 20 companies engaged in electronic components. In discussions with investors in Singapore and Hong Kong, the main topics included (1) the positioning of Murata and Taiyo Yuden in high value-added MLCCs for AI servers, (2) supply-demand and pricing of commoditized MLCCs, (3) differences between the MLCC market in 2018 and 2026, and (4) Ibiden's technological competitiveness and valuation in ABF package substrates.

Murata's MLCCs to see significant ASP growth even without price hikes due to increasing sales of high value-added products for AI servers: We expect that in AI server accelerator boards, the total capacitance required of MLCC increases at roughly twice the rate with each new generation of GPUs, while installation space remains limited, supporting continued growth in demand for compact, high-capacitance, high value-added MLCCs. Murata has advanced miniaturization and higher capacitance of MLCC not only by refining and homogenizing the particle size of barium titanate (key material) and increasing the number of layers, but also by narrowing the width of external electrodes to increase volume of dielectric layers. It plans to increase sales to AI/data centers by 85-90% YoY in F3/27, assuming volume growth of ~40% and ASP growth of ~50%. The ASP increase does not assume unit price hikes for identical products, but rather reflects a roughly 50% rise driven by a higher mix of high unit price, high value-added products. Investor interest in our meetings was almost entirely focused on the extent of price hikes in commoditized products, with little attention paid to the likelihood of earnings expansion driven by growth in high value-added products. We expect the gap in corporate value between companies that raise prices indiscriminately and those that continuously improve product competitiveness to become increasingly evident.

MORGAN STANLEY MUFG SECURITIES CO., LTD.+

Shoji Sato

Equity Analyst

Shoji.Sato@morganstanleymufg.com

+81 3 6836-8404

Sota Harashima

Equity Analyst

Sota.Harashima@morganstanleymufg.com

+81 3 6836-8897



ELECTRONIC COMPONENTS

Japan

Industry View

In-Line

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+ = Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Market share ranking for AI server high value-added MLCCs is 1) Murata, 2) SEMCO, 3)

Taiyo Yuden: We estimate MLCC market share in 2025 at 40.8% for Murata

Manufacturing, 22.5% for SEMCO, and 11.3% for Taiyo Yuden. We estimate MLCC sales for AI/data centers accounted for 10-15% of Murata's total MLCC sales in F3/26, and forecast this will increase by 85–90% YoY in F3/27 to account for 20–25% of MLCC sales, and continue growing at a similar pace from F3/28 onward. For Taiyo Yuden, we estimate AI/data center MLCC sales accounted for 5–10% of total MLCC sales in F3/26, and will increase by 82-83% YoY in F3/27 to around 15% of MLCC sales, and continue expanding at a similar pace from F3/28 onward. Demand for MLCC such as 1608 size 100μF, 1005 size 4-7μF, and 0603 size 10μF is increasing significantly in AI servers, but it appears that only Murata can stably mass-produce all of these products. While the timing of when Taiyo Yuden will achieve stable mass production of all these MLCCs remains unclear, by the time it does so for products comparable to Murata's, we think Murata is likely to be mass-producing even smaller, higher-capacitance MLCCs. Although we expect Taiyo Yuden's earnings to benefit from increased sales of MLCC for AI servers/ data centers and higher utilization rates, we believe Murata remains the only company capable of stably supplying high value-added products, and thus the contribution of high value-added products to Taiyo Yuden's earnings will likely be limited. In addition, as Taiyo Yuden froze capex in 2H 2024, we estimate MLCC production capacity growth was limited to around 5% in F3/26, constraining its ability to capture new business.

The gap between companies that implement price hikes at each opportunity and those that continuously enhance product competitiveness will become more evident over the medium to long term:

Many Japanese electronic component companies, including Murata, combine strong technological competitiveness with cost competitiveness. Many of these companies earn high levels of profit supported by their advanced products, while also maintaining strong cost competitiveness in commoditized products. Prices from distributors to customers for commoditized MLCC appear to be rising. We infer that Murata adjusts prices flexibly in line with market conditions for commoditized products. Murata does not proactively implement price hikes for commoditized products because while such increases may maximize short-term profits, they risk lowering barriers to entry, facilitating entry by companies from China, South Korea, and Taiwan, and ultimately leading to share erosion over the medium to long term. In contrast, many companies in China, South Korea, and Taiwan that pursue short-term profit maximization through indiscriminate price increases appear not to allocate sufficient resources to R&D or to improving production technology to enhance product competitiveness. While rising prices for commoditized products may boost short-term profits for companies focused on these products, we argue that they are unlikely to contribute to medium- to long-term market share gains or expansion in corporate value.

While we expect Ibiden to continue expanding earnings, market expectations appear too high:

We estimate Ibiden began volume shipments of ABF package substrates for NVIDIA's Rubin in 4Q F3/26, and expect sales of ABF package substrates for Rubin to exceed those for Blackwell in 1Q F3/27, driving continued earnings expansion through growth in high value-added ABF package substrates. We expect ABF package substrates to continue to become more value-added, driven in part by increases in SAP size. That said, we forecast OP at ¥94.7bn in F3/27 (company forecast ¥90bn, FactSet consensus ¥99.7bn), ¥128.5bn in F3/28 (company forecast ¥150bn, FS consensus ¥151.5bn), and ¥242.6bn in F3/31 (company forecast ¥300bn). While we expect continued earnings

Exhibit 1: Electronic Components Industry: Gaps between recent share prices and PTs (base, bull, bear case fair value)




Exhibit 2: Sales and OP for coverage electronic components companies

APY (bn)	F25 1Q	F25 2Q	F25 3Q	F25 4Q	F26 1Qe	F26 2Qe	F26 3Qe	F26 4Qe	F21	F22	F23	F24	F25	F26	F27e	F28	F29	F30e	F26C6 1He	F26C6 2He	F26C6 3He	F26C6 FSE	F27e FSE	F28e FSE	+1Q FSE	
Sales																										
USDJPY/Average Rate	144.5	147.5	154.0	156.9	155.0	155.0	155.0	155.0	112.4	135.4	144.5	152.5	150.6	155.0	155.0	155.0	155.0	155.0								
IBIDEN	4032	97.5	98.0	103.1	117.6	117.8	122.5	132.1	137.6	401.1	417.5	370.5	369.4	416.2	509.8	614.5	730.2	877.6	976.4	230.0	270.0	500.0	516.3	646.3	795.4	
NITERRA	4564	169.1	181.2	174.9	205.2	201.2	222.2	205.4	205.9	497.1	562.6	614.5	653.0	731.2	854.8	919.7	990.0	1068.8	391.0	399.0	790.0	786.3	841.3	959.4	1161.9	
DAIICHI KASEI	367.9	368.9	411.4	453.8	432.2	417.1	444.5	439.3	416.6	1,124.1	1,292.2	1,441.4	1,522.7	1,654.4	1,711.2	1,768.0	1,829.2	1,916.0	846.5	843.5	1,985.6	1,916.0	1,775.0	1,831.0	2,032.0	
MITSUBISHI MOTOR	6592	47.0	48.0	52.1	53.4	50.4	55.5	57.6	55.3	176.7	176.7	156.2	178.1	188.8	233.7	249.0	255.9	333.8	104.6	103.8	213.0	210.5	220.2	232.6	405.2	
TDK	6732	535.6	548.6	675.2	643.6	651.8	703.2	719.3	693.7	1,902.1	2,180.8	2,103.9	2,204.0	2,504.8	2,768.0	3,020.6	3,295.6	3,600.9	3,937.8	-	-	2,580.0	2,694.5	2,885.6	3,126.2	632.9
ALPS ALPINE	6770	238.9	266.8	255.5	258.3	251.5	271.0	276.0	266.0	820.9	933.1	964.1	990.4	1,019.5	1,064.5	1,157.6	1,222.2	1,300.1	1,385.1	508.0	537.0	1,045.0	1,079.1	1,089.9	1,117.6	243.3
NICHON DEMPMA KOGYO	6779	12.7	14.0	13.2	14.8	14.8	15.3	15.6	16.2	45.4	52.5	50.3	53.1	54.6	61.9	66.8	72.4	79.7	89.1	29.5	31.1	60.6	61.9	66.6	72.4	148.0
DAIICHI KASEI	6787	53.1	58.4	60.5	68.5	73.7	78.2	85.2	86.7	151.3	167.3	179.5	206.8	240.6	323.8	412.9	482.1	539.7	595.1	-	-	320.0	320.7	397.6	471.1	70.0
MAEKO ELECTRONIC	6806	49.0	49.0	53.1	57.2	58.6	60.0	63.0	63.0	164.0	164.0	164.0	164.0	164.0	164.0	164.0	164.0	164.0	164.0	115.0	115.0	232.0	232.0	232.0	232.0	232.0
JAE	6807	51.6	58.8	56.3	61.1	55.6	61.9	57.0	60.6	225.1	235.9	225.8	221.6	227.9	253.1	236.9	245.1	248.0	251.3	120.0	120.0	247.0	246.3	257.2	274.0	232.0
DAIICHI KASEI	6958	22.8	24.4	25.8	27.2	23.8	25.6	26.7	27.5	81.5	83.8	90.6	95.5	100.2	103.6	106.2	109.2	112.5	116.2	-	-	104.0	104.8	109.6	114.6	24.0
CAI	6962	9.4	10.2	10.0	10.0	10.2	10.6	10.1	10.0	41.3	38.4	39.3	38.6	39.6	40.4	43.4	46.2	49.1	52.3	-	-	41.0	41.1	43.6	46.2	10.2
HAMAMATSU PHOTONICS	6965	50.8	56.2	48.7	56.6	51.9	60.6	58.2	62.1	169.0	208.8	221.4	204.0	212.1	232.8	245.8	265.7	287.6	319.1	112.5	119.5	232.0	231.2	245.8	262.7	57.6
DAIICHI	6971	49.3	51.3	54.2	58.9	54.2	60.0	56.9	58.9	1,838.9	2,025.2	2,004.2	2,014.5	2,070.1	1,951.1	1,977.2	2,102.9	2,236.8	2,379.3	-	-	1,940.0	2,016.0	2,142.0	2,278.0	232.0
TAIYO YUDEN	6976	84.3	92.8	88.5	89.2	94.2	101.2	101.7	108.8	349.6	319.5	322.6	341.4	355.3	411.3	475.1	523.7	573.9	624.8	-	-	380.0	396.3	447.5	515.3	92.6
MURATA MANUFACTURING	6981	416.2	486.6	467.5	460.6	466.2	535.5	532.0	555.1	1,812.5	1,686.8	1,640.2	1,743.4	1,830.9	2,044.2	2,449.7	2,830.5	3,292.2	3,860.7	960.0	1,000.0	1,960.0	2,030.6	2,359.5	2,814.6	471.0
NICHICON	6996	39.6	41.1	43.5	45.5	42.4	44.4	49.4	50.7	142.2	147.4	181.6	175.8	169.7	187.0	197.2	207.1	220.1	237.4	-	-	185.0	192.1	207.1	218.6	45.0
NIPPON CHEMI-CON	6997	30.9	33.4	35.9	36.7	36.2	38.6	39.1	40.3	161.9	150.7	122.7	136.8	154.4	158.3	165.6	173.4	184.1	77.0	83.0	160.0	154.6	165.7	171.0	36.2	
DAIICHI	6999	17.9	18.5	19.2	19.2	19.2	19.9	19.6	20.2	65.4	65.4	64.1	64.1	64.1	64.1	64.1	64.1	64.1	64.1	38.6	38.8	77.0	78.4	79.7	79.7	79.7
TOTAL	27114	3113.2	3168.3	3205.9	3160.2	3137.1	3183.0	3232.0	1403.3	1603.7	1670.4	1427.4	1372.9	1314.6	1431.8	1568.8	1715.0	1876.6	1272.2	1305.6	1426.5	1526.8	1650.0	1663.2	1863.2	

[illegible]

Exhibit 3: Current valuation comparisons


	Rating	Price		Mkt Cap		Net Asset		EV		P/E		EV		EB Cash Pre		P/B		ROE		F24		
		26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	26/02	27/02	
IDBEN	45052	Overweight	24.00	24.00	112.8	112.8	81.1	81.1	112.8	81.1	20.0	20.0	21.0	19.0	102.8	102.8	1.0	1.0	11.0	11.0	17.4%	17.4%
NIFERRA	5334	Overweight	10.85	21.53	26.8	26.8	21.28	17.8	15.8	13.4	11.5	10.3	18.0	16.4	14.3	12.7	11.4	14.9%	15.0%	16.9%	16.9%	
45054	Overweight	10.85	21.53	26.8	26.8	21.28	17.8	15.8	13.4	11.5	10.3	18.0	16.4	14.3	12.7	11.4	11.4	14.9%	15.0%	16.9%	16.9%	
MAMBOCH MOTO	6592	Overweight	10.85	41.14	146.8	146.8	16.8	14.5	15.32	10.7	11.4	10.8	10.3	9.4	7.8	1.2	1.2	1.3	7.2%	7.9%	8.8%	9.5%
45056	Overweight	10.85	41.14	146.8	146.8	16.8	14.5	15.32	10.7	11.4	10.8	10.3	9.4	7.8	1.2	1.2	1.3	7.2%	7.9%	8.8%	9.5%	
ALPS ALFA	6770	Overweight	11.82	398.4	129.0	298.4	12.5	7.9	6.8	5.9	5.2	8.4	5.3	4.6	4.0	3.5	0.8	10.1%	10.0%	11.4%	11.9%	
45058	Overweight	11.82	398.4	129.0	298.4	12.5	7.9	6.8	5.9	5.2	8.4	5.3	4.6	4.0	3.5	0.8	10.1%	10.0%	11.4%	11.9%		
MEGAL ELECTRONICS KOYO	6787	Overweight	30.26	778.4	26.0	778.4	82.0	78.4	14.5	12.5	31.9	25.4	19.4	16.3	14.0	5.1	4.3	26.5%	20.0%	22.3%	21.9%	
45060	Overweight	30.26	778.4	26.0	778.4	82.0	78.4	14.5	12.5	31.9	25.4	19.4	16.3	14.0	5.1	4.3	26.5%	20.0%	22.3%	21.9%		
219082 ELECTRIC JAC	6801	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%
45062	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%	
CAISHINKU	6801	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%
45064	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%	
HAMAMOTO MANUFACTURING	6801	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%
45066	Overweight	2.27	157.0	10.1	156.9	22.9	21.9	20.7	19.7	19.0	21.9	21.9	19.8	18.1	1.0	1.0	1.0	4.0%	4.7%	5.0%	5.0%	
YATO YUEN	6870	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%
45068	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45070	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45072	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45074	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45076	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45078	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45080	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45082	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45084	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45086	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45088	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45090	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45092	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45094	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45096	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45098	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45100	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45102	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45104	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45106	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45108	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45110	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45112	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45114	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45116	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45118	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45120	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45122	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45124	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45126	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45128	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45130	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45132	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45134	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45136	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45138	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45140	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45142	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45144	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45146	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45148	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45150	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45152	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45154	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8	34.0	70.7	46.0	42.4	37.9	32.1	6.1	5.8	5.3	4.8%	4.3%	12.9%	13.4%	
45156	Overweight	16.28	210.9	17.0	210.9	49.2	42.8	33.8														

3


Exhibit 5 Sensitivity of OP to forex for coverage electronic components companies

		F26e	FX assumption (by company)		FX sensitivity (JPY bn/year)	Assumption:¥150/USD		Assumption:¥160/USD	
		OP (JPY bn)	USD/JPY	USD/JPY	USD/JPY	OP (JPY bn)	Change (%)	OP (JPY bn)	Change (%)
IBIDEN	4062	94.7	155.0	150.0	0.8	90.7	-4%	98.7	4%
NITERRA	5334	158.2	155.0	150.0	1.0	153.2	-3%	163.2	3%
MINEBEA MITSUMI	6479	121.5	155.0	155.0	1.5	114.0	-6%	129.0	6%
MABUCHI MOTOR	6592	27.2	155.0	150.0	0.3	25.7	-6%	28.7	6%
TDK	6762	335.8	155.0	150.0	2.0	325.8	-3%	345.8	3%
ALPS ALPINE	6770	49.1	155.0	150.0	1.2	43.1	-12%	55.1	12%
NIHON DEMPY KOGYO	6779	4.6	155.0	150.0	0.1	4.2	-9%	5.0	9%
MEIKO ELECTRONICS	6787	38.6	155.0	150.0	0.1	38.1	-1%	39.1	1%
HIROSE ELECTRIC	6806	47.3	155.0	150.0	0.3	45.7	-3%	49.0	3%
JAE	6807	8.9	155.0	153.0	0.3	7.4	-17%	10.4	17%
CMK	6958	3.2	155.0	150.0	0.0	3.2	0%	3.2	0%
DAISHINKU	6962	1.0	155.0	150.0	0.1	0.8	-25%	1.3	25%
HAMAMATSU PHOTONICS	6965	22.5	155.0	151.7	0.3	21.0	-7%	24.0	7%
KYOCERA	6971	132.6	155.0	150.0	1.0	127.6	-4%	137.6	4%
TAIYO YUDEN	6976	45.2	155.0	149.8	0.9	40.7	-10%	49.7	10%
MURATA MANUFACTURING	6981	431.9	155.0	149.1	4.5	409.4	-5%	454.4	5%
NICHICON	6996	9.4	155.0	145.0	0.1	8.9	-6%	10.0	6%
NIPPON CHEMI-CON	6997	7.0	155.0	153.0	0.3	5.7	-19%	8.3	19%
KOA	6999	3.2	150.0	157.0	0.1	3.2	0%	4.4	38%
Total		1,541.9			14.9	1,468.3	-5%	1,616.8	5%

Note: Fiscal year for Hamamatsu ends in Sep, Mabuchi ends in Dec, e=Morgan Stanley Research estimates
Source: Company data, Morgan Stanley Research

Exhibit 4: MLCC market share

Source: Company data, Morgan Stanley Research

Exhibit 5: MLCC market share (CY25)

Source: Company data, Morgan Stanley Research

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley MUFG Securities Co., Ltd. and its affiliates (collectively, "Morgan Stanley").

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Sota Harashima; Shoji Sato.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflict/policies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

As of May 29, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: ALPS ALPINE, CMK, Hamamatsu Photonics, Ibiden, IRISO Electronics, Japan Aviation Electronics Industry, KOA, Mabuchi Motor, Minebea Mitsumi, Murata Manufacturing, Nichicon, Nidec, Nihon Dempa Kogyo, Nippon Chemi-Con, Taiyo Yuden, TDK.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from IRISO Electronics, Kyocera, Mabuchi Motor, Nidec.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from ALPS ALPINE, CMK, Daishinku, Hamamatsu Photonics, Hirose Electric, Ibiden, IRISO Electronics, Japan Aviation Electronics Industry, KOA, Kyocera, Mabuchi Motor, Meiko Electronics, Minebea Mitsumi, Murata Manufacturing, Nichicon, Nidec, Nihon Dempa Kogyo, Nippon Chemi-Con, Niterra, Taiyo Yuden, TDK.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Nihon Dempa Kogyo.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Ibiden, Kyocera, Meiko Electronics, Minebea Mitsumi, Murata Manufacturing, Nidec, Niterra, TDK.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Japan Aviation Electronics Industry, Kyocera, Nihon Dempa Kogyo.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of May 31, 2026)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.

For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

Coverage Universe			Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
Stock Rating Category	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1542	42%	465	51%	30%	707	43%
Equal-weight/Hold	1571	43%	369	40%	23%	723	44%
Not-Rated/Hold	3	0%	0	0%	0%	1	0%
Underweight/Sell	551	15%	86	9%	16%	201	12%
Total	3,667		920			1632	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures.

For Morgan Stanley specific disclosures, you may refer to <https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch>.

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification Number (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Canada by Morgan Stanley Canada Limited; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 14910 and Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "FSA Order"), or (ii) are persons to whom an invitation or inducement to engage in investment activity is being communicated, or (iii) are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity is being communicated, or (iv) are persons who are exempt from the requirements of the FSA Order, or (v) are persons who are exempt from the requirements of the FSA Order, or (vi) are persons who are exempt from the requirements of the FSA Order, or (vii) are persons who are exempt from the requirements of the FSA Order, or (viii) are persons who are exempt from the requirements of the FSA Order, or (ix) are persons who are exempt from the requirements of the FSA Order, or (x) are persons who are exempt from the requirements of the FSA Order, or (xi) are persons who are exempt from the requirements of the FSA Order, or (xii) are persons who are exempt from the requirements of the FSA Order, or (xiii) are persons who are exempt from the requirements of the FSA Order, or (xiv) are persons who are exempt from the requirements of the FSA Order, or (xv) are persons who are exempt from the requirements of the FSA Order, or (xvi) are persons who are exempt from the requirements of the FSA Order, or (xvii) are persons who are exempt from the requirements of the FSA Order, or (xviii) are persons who are exempt from the requirements of the FSA Order, or (xix) are persons who are exempt from the requirements of the FSA Order, or (xx) are persons who are exempt from the requirements of the FSA Order, or (xxi) are persons who are exempt from the requirements of the FSA Order, or (xxii) are persons who are exempt from the requirements of the FSA Order, or (xxiii) are persons who are exempt from the requirements of the FSA Order, or (xxiv) are persons who are exempt from the requirements of the FSA Order, or (xxv) are persons who are exempt from the requirements of the FSA Order, or (xxvi) are persons who are exempt from the requirements of the FSA Order, or (xxvii) are persons who are exempt from the requirements of the FSA Order, or (xxviii) are persons who are exempt from the requirements of the FSA Order, or (xxix) are persons who are exempt from the requirements of the FSA Order, or (xxx) are persons who are exempt from the requirements of the FSA Order, or (xxxi) are persons who are exempt from the requirements of the FSA Order, or (xxxii) are persons who are exempt from the requirements of the FSA Order, or (xxxiii) are persons who are exempt from the requirements of the FSA Order, or (xxxiv) are persons who are exempt from the requirements of the FSA Order, or (xxxv) are persons who are exempt from the requirements of the FSA Order, or (xxxvi) are persons who are exempt from the requirements of the FSA Order, or (xxxvii) are persons who are exempt from the requirements of the FSA Order, or (xxxviii) are persons who are exempt from the requirements of the FSA Order, or (xxxix) are persons who are exempt from the requirements of the FSA Order, or (xl) are persons who are exempt from the requirements of the FSA Order, or (xli) are persons who are exempt from the requirements of the FSA Order, or (xlii) are persons who are exempt from the requirements of the FSA Order, or (xliii) are persons who are exempt from the requirements of the FSA Order, or (xliv) are persons who are exempt from the requirements of the FSA Order, or (xlv) are persons who are exempt from the requirements of the FSA Order, or (xlvi) are persons who are exempt from the requirements of the FSA Order, or (xlvii) are persons who are exempt from the requirements of the FSA Order, or (xlviii) are persons who are exempt from the requirements of the FSA Order, or (xlix) are persons who are exempt from the requirements of the FSA Order, or (l) are persons who are exempt from the requirements of the FSA Order, or (li) are persons who are exempt from the requirements of the FSA Order, or (lii) are persons who are exempt from the requirements of the FSA Order, or (liii) are persons who are exempt from the requirements of the FSA Order, or (liv) are persons who are exempt from the requirements of the FSA Order, or (lvi) are persons who are exempt from the requirements of the FSA Order, or (lvii) are persons who are exempt from the requirements of the FSA Order, or (lviii) are persons who are exempt from the requirements of the FSA Order, or (lix) are persons who are exempt from the requirements of the FSA Order, or (lx) are persons who are exempt from the requirements of the FSA Order, or (lxi) are persons who are exempt from the requirements of the FSA Order, or (lxii) are persons who are exempt from the requirements of the FSA Order, or (lxiii) are persons who are exempt from the requirements of the FSA Order, or (lxiv) are persons who are exempt from the requirements of the FSA Order, or (lxv) are persons who are exempt from the requirements of the FSA Order, or (lxvi) are persons who are exempt from the requirements of the FSA Order, or (lxvii) are persons who are exempt from the requirements of the FSA Order, or (lxviii) are persons who are exempt from the requirements of the FSA Order, or (lxix) are persons who are exempt from the requirements of the FSA Order, or (lxx) are persons who are exempt from the requirements of the FSA Order, or (lxxi) are persons who are exempt from the requirements of the FSA Order, or (lxxii) are persons who are exempt from the requirements of the FSA Order, or (lxxiii) are persons who are exempt from the requirements of the FSA Order, or (lxxiv) are persons who are exempt from the requirements of the FSA Order, or (lxxv) are persons who are exempt from the requirements of the FSA Order, or (lxxvi) are persons who are exempt from the requirements of the FSA Order, or (lxxvii) are persons who are exempt from the requirements of the FSA Order, or (lxxviii) are persons who are exempt from the requirements of the FSA Order, or (lxxix) are persons who are exempt from the requirements of the FSA Order, or (lxxx) are persons who are exempt from the requirements of the FSA Order, or (lxxxi) are persons who are exempt from the requirements of the FSA Order, or (lxxxii) are persons who are exempt from the requirements of the FSA Order, or (lxxxiii) are persons who are exempt from the requirements of the FSA Order, or (lxxxiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxv) are persons who are exempt from the requirements of the FSA Order, or (lxxxvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxix) are persons who are exempt from the requirements of the FSA Order, or (lxxxx) are persons who are exempt from the requirements of the FSA Order, or (lxxxxi) are persons who are exempt from the requirements of the FSA Order, or (lxxxxii) are persons who are exempt from the requirements of the FSA Order, or (lxxxxiii) are persons who are exempt from the requirements of the FSA Order, or (lxxxxiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxxv) are persons who are exempt from the requirements of the FSA Order, or (lxxxxvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxxvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxxviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxxix) are persons who are exempt from the requirements of the FSA Order, or (lxxxxx) are persons who are exempt from the requirements of the FSA Order, or (lxxxxxi) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlv) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvi) are persons who are exempt from the requirements of the FSA Order, or (lxxxlvii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlviii) are persons who are exempt from the requirements of the FSA Order, or (lxxxlix) are persons who are exempt from the requirements of the FSA Order, or (lxxxli) are persons who are exempt from the requirements of the FSA Order, or (lxxxlii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliii) are persons who are exempt from the requirements of the FSA Order, or (lxxxliiv) are persons who are exempt from the requirements of



The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

INDUSTRY COVERAGE: Electronic Components

COMPANY (TICKER)	RATING (AS OF)	PRICE* (06/26/2026)
Shoji Sato		
ALPS ALPINE (6770.T)	O (03/17/2026)	¥1,982
Hamamatsu Photonics (6965.T)	E (06/17/2026)	¥2,625
Ibiden (4062.T)	U (02/04/2026)	¥24,000
Kyocera (6971.T)	E (06/25/2020)	¥3,411
Mabuchi Motor (6592.T)	E (11/03/2022)	¥1,609
Minebea Mitsumi (6479.T)	E (10/23/2025)	¥4,805
Murata Manufacturing (6981.T)	O (11/26/2025)	¥10,770
Nidec (6594.T)	NR (09/05/2025)	¥2,543
Niterra (5334.T)	O (01/17/2024)	¥10,845
Taiyo Yuden (6976.T)	U (06/17/2026)	¥16,780
TDK (6762.T)	O (08/02/2022)	¥3,575
Sota Harashima		
CMK (6958.T)	E (02/28/2025)	¥657
Daishinku (6962.T)	U (06/17/2026)	¥923
Hirose Electric (6806.T)	O (07/10/2024)	¥29,660
IRISO Electronics (6908.T)	E (08/02/2022)	¥2,957
Japan Aviation Electronics Industry (6807.T)	E (01/17/2024)	¥2,276
KOA (6999.T)	E (06/17/2026)	¥2,929
Meiko Electronics (6787.T)	E (04/03/2026)	¥30,250
Nichicon (6996.T)	E (11/10/2021)	¥4,300
Nihon Dempa Kogyo (6779.T)	E (03/07/2024)	¥3,890
Nippon Chemi-Con (6997.T)	U (09/20/2024)	¥5,590

Stock Ratings are subject to change. Please see latest research for each company.

* Historical prices are not split adjusted.